File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs

TitleNausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs
Authors
KeywordsChemicals And Cas Registry Numbers
Issue Date2002
Citation
Zhonghua zhong liu za zhi [Chinese journal of oncology], 2002, v. 24 n. 5, p. 504-507 How to Cite?
AbstractOBJECTIVE: To evaluate the efficacy and safety of nausea oral, disintegrating buccal tablet (DBT) in the prevention of gastrointestinal reaction induced by anticancer drugs (cisplatin DDP 30 - 50 mg/m(2) or adramycin ADM >/= 40 mg/m(2)), as compared with those of kytril tablets. METHODS: A multicenter, open and randomized self-crossover control trial was carried out with all the eligible patients randomized into AB or BA group. Patients in AB group were given nausea 0.1 mg as buccal tablet one hour before chemotherapy in the first cycle and kytril tablet 2 mg in the second cycle, those in BA group were given these drugs in the reverse order. RESULTS: Seventy-three patients were allotted to this study, including 44 patients in DDP-arm and 29 in ADM-arm. Sixty-two patients were evaluable for response and 70 patients for safety. Nausea DBT was as effective as kytril tablet in the control of anorexia, nausea and vomiting during the first 24 hours after chemotherapy, with response rates of 74.2%, 77.4%, 83.9% in nausea DBT and 74.2%, 71.0%, 88.7% DBT in kytril tablets. A high efficacy in the control of vommitting induced by cisplatin was observed in both nausea DBT and kytril tablets. The complete control rates and overall control rates were 83.3%, 91.7% in nausea DBT and 86.1%, 97.2% in kytril tablets, respectively. The side effects of nausea DBT were head heaviness, dry mouth and somnolence, which were mild and comparable with kytril in their frequencies. CONCLUSION: Nausea disintegrating buccal tablet is able to effectively prevent gastrointestinal reaction induced by anticancer drugs, with efficacy and side effects similar to kytril tablets. Nausea DB tablet, an intraoral disintegrator, is very convenient for patients who can not swallow tablets for various reasons.
Persistent Identifierhttp://hdl.handle.net/10722/92238
ISSN
2015 SCImago Journal Rankings: 0.190

 

DC FieldValueLanguage
dc.contributor.authorZhang, Pen_HK
dc.contributor.authorFeng, Fen_HK
dc.contributor.authorHe, Yen_HK
dc.contributor.authorLi, Yen_HK
dc.contributor.authorZhou, Men_HK
dc.contributor.authorCheng, Gen_HK
dc.contributor.authorChen, Yen_HK
dc.date.accessioned2010-09-17T10:40:09Z-
dc.date.available2010-09-17T10:40:09Z-
dc.date.issued2002en_HK
dc.identifier.citationZhonghua zhong liu za zhi [Chinese journal of oncology], 2002, v. 24 n. 5, p. 504-507en_HK
dc.identifier.issn0253-3766en_HK
dc.identifier.urihttp://hdl.handle.net/10722/92238-
dc.description.abstractOBJECTIVE: To evaluate the efficacy and safety of nausea oral, disintegrating buccal tablet (DBT) in the prevention of gastrointestinal reaction induced by anticancer drugs (cisplatin DDP 30 - 50 mg/m(2) or adramycin ADM >/= 40 mg/m(2)), as compared with those of kytril tablets. METHODS: A multicenter, open and randomized self-crossover control trial was carried out with all the eligible patients randomized into AB or BA group. Patients in AB group were given nausea 0.1 mg as buccal tablet one hour before chemotherapy in the first cycle and kytril tablet 2 mg in the second cycle, those in BA group were given these drugs in the reverse order. RESULTS: Seventy-three patients were allotted to this study, including 44 patients in DDP-arm and 29 in ADM-arm. Sixty-two patients were evaluable for response and 70 patients for safety. Nausea DBT was as effective as kytril tablet in the control of anorexia, nausea and vomiting during the first 24 hours after chemotherapy, with response rates of 74.2%, 77.4%, 83.9% in nausea DBT and 74.2%, 71.0%, 88.7% DBT in kytril tablets. A high efficacy in the control of vommitting induced by cisplatin was observed in both nausea DBT and kytril tablets. The complete control rates and overall control rates were 83.3%, 91.7% in nausea DBT and 86.1%, 97.2% in kytril tablets, respectively. The side effects of nausea DBT were head heaviness, dry mouth and somnolence, which were mild and comparable with kytril in their frequencies. CONCLUSION: Nausea disintegrating buccal tablet is able to effectively prevent gastrointestinal reaction induced by anticancer drugs, with efficacy and side effects similar to kytril tablets. Nausea DB tablet, an intraoral disintegrator, is very convenient for patients who can not swallow tablets for various reasons.en_HK
dc.languageengen_HK
dc.relation.ispartofZhonghua zhong liu za zhi [Chinese journal of oncology]en_HK
dc.subjectChemicals And Cas Registry Numbersen_HK
dc.titleNausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugsen_HK
dc.typeArticleen_HK
dc.identifier.emailChen, Y:ychenc@hkucc.hku.hken_HK
dc.identifier.authorityChen, Y=rp1318en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid12485511-
dc.identifier.scopuseid_2-s2.0-1842848042en_HK
dc.identifier.volume24en_HK
dc.identifier.issue5en_HK
dc.identifier.spage504en_HK
dc.identifier.epage507en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats